November 14,2020: Serum Institute of India duniya laga sobse dagor vaccine maker khan para AstraZeneca’s Covid-19 shot bona toh uthai ase etu bi 100 million doses khan tayari kuribole nimete December moina tak inoculation drive nimete etu toh eki moina te India te shuru kuribole nishena ase. SII aro Indian Council of Medical Research (ICMR) khan vaccine laga clinical trials nimete mili ase. Aro ICMR para clinical trial site fees nimete fund kurishe. SII khan dusra expenses khan sai ase Covishield nimete. Etia SII aro ICMR khan para vaccine laga II/III clinical trial desh laga 15 alag alag centres te loi ase.
Adar Poonawalla, chief executive officer Pune-based firm parta kuwa te Bloomberg para koikena janaishe “judi final-stage trial data te dikhaishe koile toh AstraZeneca’s candidate para bhal protection deh koikena etu virus para Serum Institute of India – kun khan milishe komti hoilebi one billion doses – olabole nimete emergency authorisation New delhi te December para pabole nimete.”
SII khan akhe para hi 40 million doses vaccines nimete olaishe risk manufacturing aro stockpiling licence bithor te Drugs Controller General of India para dikena .etu institute laga aim toh Novavax’s contender joldi olabole nimete ase.
Poonawalla para koi kena janaishe ki”ami khan olop monchinta ase ki etu toh ekta dangor risk ase koikena .”aro koikena janaishe ki AstraZeneca aro Novavax’s shots toh bhal dikhi ase.
Covishield toh SII Pune laboratory te bona ase master seed logote Oxford University/Astra Zeneca para.etu vaccine toh UK te bona toh etia test kuri ase efficacy trials te UK, Brazil, South Africa aro US.aro etu trials laga results toh thik thaka nimete etu toh bhabona kuri ase ki Covishield toh ekta realistic solution thakibole nimete pandemic nimete.
Add Comment